DnB Asset Management’s Pfizer PFE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$55.2M Buy
1,965,182
+212,096
+12% +$5.65M 0.2% 87
2025
Q4
$43.7M Buy
1,753,086
+486,895
+38% +$12.3M 0.15% 95
2025
Q3
$32.3M Sell
1,266,191
-25,566
-2% -$631K 0.12% 128
2025
Q2
$31.3M Buy
1,291,757
+99,031
+8% +$2.31M 0.13% 120
2025
Q1
$30.2M Sell
1,192,726
-700,670
-37% -$18.3M 0.14% 120
2024
Q4
$50.2M Buy
1,893,396
+352,515
+23% +$9.56M 0.22% 73
2024
Q3
$44.6M Buy
1,540,881
+96,356
+7% +$2.81M 0.2% 87
2024
Q2
$40.4M Buy
1,444,525
+83,153
+6% +$2.29M 0.19% 83
2024
Q1
$37.8M Sell
1,361,372
-1,866,024
-58% -$51.8M 0.2% 88
2023
Q4
$92.9M Buy
3,227,396
+153,719
+5% +$4.65M 0.48% 38
2023
Q3
$102M Buy
3,073,677
+138,558
+5% +$4.9M 0.61% 27
2023
Q2
$108M Buy
2,935,119
+54,410
+2% +$2.12M 0.62% 32
2023
Q1
$118M Buy
2,880,709
+34,088
+1% +$1.47M 0.75% 25
2022
Q4
$146M Buy
2,846,621
+14,783
+0.5% +$709K 1.03% 15
2022
Q3
$124M Sell
2,831,838
-30,579
-1% -$1.49M 0.96% 17
2022
Q2
$150M Sell
2,862,417
-170,863
-6% -$8.71M 1.06% 14
2022
Q1
$157M Buy
3,033,280
+817,416
+37% +$42.4M 0.93% 17
2021
Q4
$131M Sell
2,215,864
-32,857
-1% -$1.63M 0.77% 20
2021
Q3
$96.7M Sell
2,248,721
-24,311
-1% -$1.08M 0.63% 28
2021
Q2
$89M Buy
2,273,032
+114,370
+5% +$4.45M 0.59% 27
2021
Q1
$78.2M Sell
2,158,662
-1,330,821
-38% -$47.3M 0.57% 30
2020
Q4
$128M Sell
3,489,483
-388,744
-10% -$14.3M 1.13% 14
2020
Q3
$135M Sell
3,878,227
-575,607
-13% -$20.2M 1.44% 14
2020
Q2
$138M Sell
4,453,834
-192,916
-4% -$6.55M 1.62% 10
2020
Q1
$144M Buy
4,646,750
+1,276,578
+38% +$43.5M 2.12% 9
2019
Q4
$125M Sell
3,370,172
-565,510
-14% -$20.1M 1.23% 17
2019
Q3
$134M Buy
3,935,682
+2,781,372
+241% +$101M 1.51% 12
2019
Q2
$47.4M Buy
1,154,310
+21,134
+2% +$839K 0.55% 39
2019
Q1
$45.7M Sell
1,133,176
-96,925
-8% -$3.88M 0.52% 40
2018
Q4
$50.9M Sell
1,230,101
-185,766
-13% -$7.71M 0.66% 35
2018
Q3
$59.2M Buy
1,415,867
+123,305
+10% +$4.75M 0.67% 36
2018
Q2
$44.5M Buy
1,292,562
+73,990
+6% +$2.53M 0.53% 42
2018
Q1
$41M Buy
1,218,572
+279,205
+30% +$9.6M 0.49% 45
2017
Q4
$32.3M Buy
939,367
+288,099
+44% +$9.82M 0.39% 55
2017
Q3
$22.1M Sell
651,268
-320,676
-33% -$10.3M 0.29% 74
2017
Q2
$31M Buy
971,944
+27,720
+3% +$874K 0.45% 52
2017
Q1
$30.6M Sell
944,224
-1,230,802
-57% -$38.8M 0.48% 51
2016
Q4
$67M Sell
2,175,026
-780,276
-26% -$23.8M 1.23% 17
2016
Q3
$95M Buy
2,955,302
+27,615
+0.9% +$923K 1.87% 7
2016
Q2
$97.8M Buy
2,927,687
+264,870
+10% +$8.45M 2.07% 9
2016
Q1
$74.9M Buy
2,662,817
+409,268
+18% +$11.7M 1.56% 13
2015
Q4
$69M Sell
2,253,549
-178,716
-7% -$5.62M 1.48% 16
2015
Q3
$72.5M Buy
2,432,265
+205,211
+9% +$6.58M 1.81% 11
2015
Q2
$70.8M Buy
2,227,054
+277,960
+14% +$9.06M 1.56% 13
2015
Q1
$64.3M Sell
1,949,094
-1,176,664
-38% -$37.4M 1.43% 16
2014
Q4
$92.4M Buy
3,125,758
+78,454
+3% +$2.25M 2.09% 6
2014
Q3
$85.5M Buy
3,047,304
+2,542,479
+504% +$71.4M 1.88% 9
2014
Q2
$14.2M Buy
+504,825
New +$14.4M 0.3% 72
2013
Q4
$15.8M Buy
544,855
+220,075
+68% +$6.41M 0.37% 67
2013
Q3
$8.85M Sell
324,780
-1,899,064
-85% -$51.7M 0.24% 76
2013
Q2
$59.1M Buy
+2,223,844
New +$61.4M 1.75% 12

Other funds holding PFE

DnB Asset Management's PFE Position: Q1 2026 in Review

DnB Asset Management increased its Pfizer (PFE) stake by 12% in Q1 2026, buying an estimated $5.65M and bringing the position to 1,965,182 shares worth $55.2M. The position accounts for 0.2% of the portfolio, ranked #87.

DnB Asset Management first reported a position in PFE in Q2 2013 and has held it in 51 quarters since. The position peaked at $157M in Q1 2022. 2,934 funds tracked by Wall St. Rank hold PFE as of Q1 2026.

  • DnB Asset Management held 1,965,182 shares of Pfizer worth $55.2M as of Q1 2026.
  • DnB Asset Management bought 212,096 Pfizer shares in Q1 2026, an estimated $5.65M.
  • Pfizer made up 0.2% of DnB Asset Management's portfolio in Q1 2026, its #87 holding.
  • DnB Asset Management first reported a position in Pfizer in Q2 2013 and has held it in 51 quarters since.
  • DnB Asset Management's Pfizer position peaked at $157M in Q1 2022.
  • 2,934 funds tracked by Wall St. Rank held Pfizer as of Q1 2026.

Based on DnB Asset Management's 13F filing for Q1 2026, filed 14 May 2026.